{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:32:02Z","timestamp":1791613922874,"version":"4.3.4"},"reference-count":162,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82102714"],"award-info":[{"award-number":["82102714"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273186"],"award-info":[{"award-number":["82273186"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2021YFF0704800"],"award-info":[{"award-number":["2021YFF0704800"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009991","name":"Jilin Province Department of Finance","doi-asserted-by":"publisher","award":["JLSWSRCZX2023-111"],"award-info":[{"award-number":["JLSWSRCZX2023-111"]}],"id":[{"id":"10.13039\/501100009991","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010211","name":"The Education Department of Jilin Province","doi-asserted-by":"publisher","award":["JJKH20231213KJ"],"award-info":[{"award-number":["JJKH20231213KJ"]}],"id":[{"id":"10.13039\/501100010211","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013061","name":"Jilin Scientific and Technological Development Program","doi-asserted-by":"publisher","award":["YDZJ202201ZYTS098"],"award-info":[{"award-number":["YDZJ202201ZYTS098"]}],"id":[{"id":"10.13039\/501100013061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genes & Diseases"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.gendis.2026.102230","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:06:05Z","timestamp":1778763965000},"page":"102230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Influence of oncogenic drivers and signaling pathways on immune checkpoint inhibitor efficacy in NSCLC"],"prefix":"10.1016","volume":"14","author":[{"given":"Chunyan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4720-4225","authenticated-orcid":false,"given":"Jingtao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.gendis.2026.102230_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"10.1016\/j.gendis.2026.102230_bib2","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification","volume":"10","author":"Travis","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"5676","key":"10.1016\/j.gendis.2026.102230_bib3","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"issue":"21","key":"10.1016\/j.gendis.2026.102230_bib4","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"issue":"10027","key":"10.1016\/j.gendis.2026.102230_bib5","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.gendis.2026.102230_bib6","doi-asserted-by":"crossref","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","article-title":"Non-small cell lung cancer, version 3.2022,NCCN clinical practice guidelines in oncology","volume":"20","author":"Ettinger","year":"2022","journal-title":"J Natl Compr Cancer Netw"},{"issue":"6","key":"10.1016\/j.gendis.2026.102230_bib7","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"10.1016\/j.gendis.2026.102230_bib8","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.gendis.2026.102230_bib9","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0522","article-title":"Tumor mutational burden as a predictive biomarker in solid tumors","volume":"10","author":"Sha","year":"2020","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.gendis.2026.102230_bib10","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/1078-0432.CCR-20-3054","article-title":"Tumor mutational burden as a predictor of immunotherapy response: is more always better?","volume":"27","author":"Strickler","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.gendis.2026.102230_bib11","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.2017.75.3384","article-title":"Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing","volume":"36","author":"Rizvi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.gendis.2026.102230_bib12","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.annonc.2024.06.014","article-title":"Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer","volume":"35","author":"Di Federico","year":"2024","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.gendis.2026.102230_bib13","doi-asserted-by":"crossref","first-page":"5715","DOI":"10.3390\/curroncol29080451","article-title":"Detection of potential mutated genes associated with common immunotherapy biomarkers in non-small-cell lung cancer patients","volume":"29","author":"Cao","year":"2022","journal-title":"Curr Oncol"},{"issue":"10026","key":"10.1016\/j.gendis.2026.102230_bib14","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","article-title":"Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)","volume":"387","author":"Barlesi","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.gendis.2026.102230_bib15","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1634\/theoncologist.2016-0030","article-title":"Comprehensive genomic profiling facilitates implementation of the national comprehensive cancer network guidelines for lung cancer biomarker testing and identifies patients who may benefit from enrollment in mechanism-driven clinical trials","volume":"21","author":"Suh","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.gendis.2026.102230_bib16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.canlet.2019.10.027","article-title":"The superior efficacy of anti-PD-1\/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity","volume":"470","author":"Liu","year":"2020","journal-title":"Cancer Lett"},{"issue":"8","key":"10.1016\/j.gendis.2026.102230_bib17","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.gendis.2026.102230_bib18","doi-asserted-by":"crossref","first-page":"952","DOI":"10.7150\/jca.77199","article-title":"The real-world therapeutic analysis of first-line immunotherapy in Chinese patients with drive gene positive for advanced non-small cell lung cancer","volume":"14","author":"Liu","year":"2023","journal-title":"J Cancer"},{"key":"10.1016\/j.gendis.2026.102230_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.968064","article-title":"KRAS G12 isoforms exert influence over up-front treatments: a retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population","volume":"12","author":"Fancelli","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.gendis.2026.102230_bib20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.lungcan.2022.12.019","article-title":"Large-scale clinico-genomic profile of non-small cell lung cancer with KRAS G12C: results from LC-SCRUM-Asia study","volume":"176","author":"Tamiya","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.gendis.2026.102230_bib21","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.lungcan.2023.02.021","article-title":"KRAS G12C mutated advanced non-small cell lung cancer (NSCLC): Characteristics, treatment patterns and overall survival from a Danish nationwide observational register study","volume":"178","author":"Frost","year":"2023","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.gendis.2026.102230_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103473","article-title":"Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort","volume":"9","author":"Thomas","year":"2024","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.gendis.2026.102230_bib23","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.57187\/s.3695","article-title":"Prognostic value of KRAS G12C in advanced non-small cell lung cancer with high PD-L1 expression treated with upfront immunotherapy: a systematic review and meta-analysis","volume":"154","author":"Erhart","year":"2024","journal-title":"Swiss Med Wkly"},{"issue":"12","key":"10.1016\/j.gendis.2026.102230_bib24","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","article-title":"Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma","volume":"23","author":"Dong","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.gendis.2026.102230_bib25","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jtho.2023.12.015","article-title":"Outcome of first-line treatment with pembrolizumab according to KRAS\/TP53 mutational status for nonsquamous programmed death-ligand 1-high (\u226550%) NSCLC in the German national network genomic medicine lung cancer","volume":"19","author":"Bischoff","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.gendis.2026.102230_bib26","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41416-024-02746-z","article-title":"KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma","volume":"131","author":"Budczies","year":"2024","journal-title":"Br J Cancer"},{"issue":"24","key":"10.1016\/j.gendis.2026.102230_bib27","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1158\/1078-0432.CCR-22-3655","article-title":"Facts and hopes on RAS inhibitors and cancer immunotherapy","volume":"29","author":"Boumelha","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"25","key":"10.1016\/j.gendis.2026.102230_bib28","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in advanced solid tumors harboring a KRASG12C Mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gendis.2026.102230_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113911","article-title":"Sotorasib in KRAS G12C-mutated non-small cell lung cancer: a multicenter real-world experience from the compassionate use program in Germany","volume":"201","author":"Stratmann","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.gendis.2026.102230_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.116058","article-title":"Unveiling the role of KRAS in tumor immune microenvironment","volume":"171","author":"Xu","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"29","key":"10.1016\/j.gendis.2026.102230_bib31","doi-asserted-by":"crossref","first-page":"eabm8780","DOI":"10.1126\/sciadv.abm8780","article-title":"Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers","volume":"8","author":"Mugarza","year":"2022","journal-title":"Sci Adv"},{"issue":"5","key":"10.1016\/j.gendis.2026.102230_bib32","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.3390\/cancers14051321","article-title":"Direct targeting KRAS mutation in non-small cell lung cancer: focus on resistance","volume":"14","author":"Reita","year":"2022","journal-title":"Cancers"},{"issue":"25","key":"10.1016\/j.gendis.2026.102230_bib33","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRASG12C inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.gendis.2026.102230_bib34","doi-asserted-by":"crossref","first-page":"OF2","DOI":"10.1158\/2159-8290.CD-NB2022-0081","article-title":"Frontline promise for Adagrasib-Pembrolizumab combination","volume":"13","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.gendis.2026.102230_bib35","article-title":"Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: a brief report","volume":"36","author":"Desai","year":"2023","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.gendis.2026.102230_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105074","article-title":"Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis","volume":"102","author":"Ernst","year":"2024","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.gendis.2026.102230_bib37","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1158\/1535-7163.MCT-20-0462","article-title":"The KRASG12C inhibitor MRTX849 reconditions the tumor immune microenvironment and sensitizes tumors to checkpoint inhibitor therapy","volume":"20","author":"Briere","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"10.1016\/j.gendis.2026.102230_bib38","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.21037\/tlcr-24-372","article-title":"Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients with rare KRAS mutations: a real-world retrospective study","volume":"13","author":"Jiang","year":"2024","journal-title":"Transl Lung Cancer Res"},{"issue":"14","key":"10.1016\/j.gendis.2026.102230_bib39","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1002\/cncr.32876","article-title":"Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: analysis of over 8000 cases","volume":"126","author":"Mack","year":"2020","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.gendis.2026.102230_bib40","doi-asserted-by":"crossref","first-page":"820","DOI":"10.3390\/biom14070820","article-title":"EGFR mutation and TKI treatment promote secretion of small extracellular vesicle PD-L1 and contribute to immunosuppression in NSCLC","volume":"14","author":"Liu","year":"2024","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.gendis.2026.102230_bib41","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1186\/s12967-024-05456-5","article-title":"EGFR mutations induce the suppression of CD8+ T cell and anti-PD-1 resistance via ERK1\/2-p90RSK-TGF-\u03b2 axis in non-small cell lung cancer","volume":"22","author":"Huang","year":"2024","journal-title":"J Transl Med"},{"issue":"3","key":"10.1016\/j.gendis.2026.102230_bib42","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/1759-7714.14267","article-title":"Treatment with immune checkpoint inhibitors after EGFR-TKIs in EGFR-mutated lung cancer","volume":"13","author":"Ito","year":"2022","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.gendis.2026.102230_bib43","article-title":"The efficacy of immune checkpoint inhibitors in advanced EGFR-mutated non-small cell lung cancer after resistance to EGFR-TKIs: real-world evidence from a multicenter retrospective study","volume":"13","author":"Hu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.gendis.2026.102230_bib44","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.lungcan.2020.02.010","article-title":"PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy","volume":"142","author":"Chen","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.gendis.2026.102230_bib93","article-title":"Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.gendis.2026.102230_bib45","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/cam4.2037","article-title":"Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer","volume":"8","author":"Yamada","year":"2019","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.gendis.2026.102230_bib46","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.cllc.2020.12.015","article-title":"Subtypes of EGFR- and HER2-mutant metastatic NSCLC influence response to immune checkpoint inhibitors","volume":"22","author":"Lau","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.gendis.2026.102230_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107933","article-title":"Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimen","volume":"195","author":"Liu","year":"2024","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.gendis.2026.102230_bib48","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00262-020-02662-0","article-title":"Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors","volume":"70","author":"Ichihara","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.gendis.2026.102230_bib49","article-title":"Patients with short PFS to EGFR-TKIs predicted better response to subsequent anti-PD-1\/PD-L1 based immunotherapy in EGFR common mutation NSCLC","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.gendis.2026.102230_bib50","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s00262-023-03370-1","article-title":"Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer","volume":"72","author":"Morimoto","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.gendis.2026.102230_bib51","article-title":"Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1\u226550% who developed EGFR-TKI resistance","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.gendis.2026.102230_bib52","doi-asserted-by":"crossref","first-page":"6489","DOI":"10.3390\/ijms23126489","article-title":"EGFR-mutated non-small cell lung cancer and resistance to immunotherapy: role of the tumor microenvironment","volume":"23","author":"Madeddu","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.gendis.2026.102230_bib53","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1158\/1078-0432.CCR-19-2027","article-title":"Impact of EGFR-TKI treatment on the tumor immune microenvironment in EGFR mutation-positive non-small cell lung cancer","volume":"26","author":"Isomoto","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.gendis.2026.102230_bib54","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jtho.2018.11.028","article-title":"Pembrolizumab in combination with erlotinib or gefitinib as first-line therapy for advanced NSCLC with sensitizing EGFR mutation","volume":"14","author":"Yang","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.gendis.2026.102230_bib55","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s11523-019-00658-0","article-title":"Phase I trial of targeted EGFR or ALK therapy with ipilimumab in metastatic NSCLC with long-term Follow-Up","volume":"14","author":"Chalmers","year":"2019","journal-title":"Targeted Oncol"},{"key":"10.1016\/j.gendis.2026.102230_bib56","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.lungcan.2018.12.015","article-title":"Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H","volume":"130","author":"Gubens","year":"2019","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.gendis.2026.102230_bib57","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.142843","article-title":"Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC","volume":"7","author":"Tu","year":"2022","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.gendis.2026.102230_bib58","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/s12967-019-2036-7","article-title":"The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients","volume":"17","author":"Lin","year":"2019","journal-title":"J Transl Med"},{"key":"10.1016\/j.gendis.2026.102230_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102335","article-title":"How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC)","volume":"103","author":"Tabb\u00f2","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.gendis.2026.102230_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103008","article-title":"A BRAF new world","volume":"152","author":"Frisone","year":"2020","journal-title":"Crit Rev Oncol"},{"issue":"2","key":"10.1016\/j.gendis.2026.102230_bib61","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.annonc.2019.10.022","article-title":"Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations","volume":"31","author":"Mazieres","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.gendis.2026.102230_bib62","article-title":"BRAF-mutated non-small cell lung cancer: current treatment status and future perspective","volume":"12","author":"Yan","year":"2022","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.gendis.2026.102230_bib63","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(16)30146-2","article-title":"Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial","volume":"17","author":"Planchard","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.gendis.2026.102230_bib64","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","article-title":"Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial","volume":"18","author":"Planchard","year":"2017","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.gendis.2026.102230_bib65","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1634\/theoncologist.2017-0642","article-title":"FDA approval summary: dabrafenib and trametinib for the treatment of metastatic non-small cell lung cancers harboring BRAF V600E mutations","volume":"23","author":"Odogwu","year":"2018","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.gendis.2026.102230_bib66","article-title":"Real-world treatment patterns and effectiveness of targeted and immune checkpoint inhibitor-based systemic therapy in BRAF mutation-positive NSCLC","volume":"4","author":"Gibson","year":"2023","journal-title":"JTO Clin Res Rep"},{"issue":"21","key":"10.1016\/j.gendis.2026.102230_bib67","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1200\/JCO.23.00774","article-title":"Phase II, open-label study of encorafenib plus binimetinib in patients with BRAFV600-mutant metastatic non-small-cell lung cancer","volume":"41","author":"Riely","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gendis.2026.102230_bib68","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejca.2021.02.036","article-title":"BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy","volume":"149","author":"Wiesweg","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.gendis.2026.102230_bib69","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41419-022-05510-4","article-title":"Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer","volume":"13","author":"Li","year":"2022","journal-title":"Cell Death Dis"},{"issue":"8","key":"10.1016\/j.gendis.2026.102230_bib70","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002891","article-title":"Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer","volume":"9","author":"Negrao","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.gendis.2026.102230_bib71","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jtho.2019.12.129","article-title":"Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced NSCLC with BRAF, HER2, or MET mutations or RET translocation: GFPC 01-2018","volume":"15","author":"Guisier","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.gendis.2026.102230_bib72","doi-asserted-by":"crossref","first-page":"219","DOI":"10.21037\/tlcr-22-613","article-title":"Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutations","volume":"12","author":"Wang","year":"2023","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"10.1016\/j.gendis.2026.102230_bib73","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1186\/s12885-024-12554-6","article-title":"Efficacy of chemotherapy plus immune checkpoint inhibitors in patients with non-small cell lung cancer who have rare oncogenic driver mutations: a retrospective analysis","volume":"24","author":"Yamaguchi","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.gendis.2026.102230_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107865","article-title":"BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC","volume":"194","author":"Provencio","year":"2024","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.gendis.2026.102230_bib75","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1097\/CM9.0000000000003055","article-title":"The Lung Cancer Expert Group of Chinese Medical Association Publishing House. Chinese expert consensus on immunotherapy for advanced non-small cell lung cancer with oncogenic driver mutations (2023 edition)","volume":"137","year":"2024","journal-title":"Chin Med J"},{"issue":"7","key":"10.1016\/j.gendis.2026.102230_bib76","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.3390\/ijms21072623","article-title":"Efficacy of immune checkpoint inhibitor monotherapy for advanced non-small-cell lung cancer with ALK rearrangement","volume":"21","author":"Oya","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.gendis.2026.102230_bib77","article-title":"Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.gendis.2026.102230_bib78","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.21037\/tlcr-22-619","article-title":"Advancements of ALK inhibition of non-small cell lung cancer: a literature review","volume":"12","author":"Zia","year":"2023","journal-title":"Transl Lung Cancer Res"},{"issue":"3","key":"10.1016\/j.gendis.2026.102230_bib79","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/s43018-023-00515-0","article-title":"ALK-positive lung cancer: a moving target","volume":"4","author":"Schneider","year":"2023","journal-title":"Nat Cancer"},{"issue":"3","key":"10.1016\/j.gendis.2026.102230_bib80","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jtho.2019.10.006","article-title":"Ceritinib plus nivolumab in patients with advanced ALK-rearranged non\u2013small cell lung cancer: results of an open-label, multicenter, phase 1B study","volume":"15","author":"Felip","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.gendis.2026.102230_bib81","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.lungcan.2020.05.008","article-title":"Complete and prolonged response to anti-PD1 therapy in an ALK rearranged lung adenocarcinoma","volume":"146","author":"Baldacci","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.gendis.2026.102230_bib82","article-title":"A case of remarkable response to atezolizumab in ALK-translocated metastatic lung adenocarcinoma","volume":"34","author":"Von","year":"2021","journal-title":"Respir Med Case Rep"},{"issue":"5","key":"10.1016\/j.gendis.2026.102230_bib83","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jtho.2018.02.022","article-title":"Phase 1\/2 study of the safety and tolerability of nivolumab plus crizotinib for the first-line treatment of anaplastic lymphoma kinase translocation - positive advanced non-small cell lung cancer (CheckMate 370)","volume":"13","author":"Spigel","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"7","key":"10.1016\/j.gendis.2026.102230_bib84","doi-asserted-by":"crossref","first-page":"562-e1012","DOI":"10.1634\/theoncologist.2020-0034","article-title":"Phase ib study of crizotinib plus pembrolizumab in patients with previously untreated advanced non-small cell lung cancer with ALK translocation","volume":"25","author":"Patel","year":"2020","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.gendis.2026.102230_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100342","article-title":"Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I\/II study","volume":"7","author":"Lin","year":"2022","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.gendis.2026.102230_bib86","article-title":"Response to immune checkpoint inhibition as monotherapy or in combination with chemotherapy in metastatic ROS1-rearranged lung cancers","volume":"2","author":"Choudhury","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.gendis.2026.102230_bib87","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.527750","article-title":"ROS1 fusion mediates immunogenicity by upregulation of PD-L1 after the activation of ROS1-SHP2 signaling pathway in non-small cell lung cancer","volume":"11","author":"Cai","year":"2020","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.gendis.2026.102230_bib88","doi-asserted-by":"crossref","DOI":"10.1200\/PO.22.00614","article-title":"Efficacy of immune checkpoint inhibitor plus chemotherapy in patients with ROS1-rearranged advanced lung adenocarcinoma: a multicenter, retrospective cohort study","author":"Huang","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.gendis.2026.102230_bib89","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2023.01.014","volume":"183","author":"Bylicki","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.gendis.2026.102230_bib90","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41698-024-00720-9","article-title":"Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients","volume":"8","author":"Hong","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.gendis.2026.102230_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107992","article-title":"Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: results from LC-SCRUM-Asia","volume":"197","author":"Kato","year":"2024","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.gendis.2026.102230_bib92","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1186\/s12885-024-12748-y","article-title":"Clinical outcomes for immune checkpoint inhibitors plus chemotherapy in non-small-cell lung cancer patients with uncommon driver gene alterations","volume":"24","author":"Qin","year":"2024","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.gendis.2026.102230_bib94","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/cac2.12327","article-title":"KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1\/PD-L1 immunotherapy in non-small cell lung cancer","volume":"42","author":"Liu","year":"2022","journal-title":"Cancer Commun"},{"issue":"6","key":"10.1016\/j.gendis.2026.102230_bib95","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jtho.2023.01.091","article-title":"Clinicopathologic and genomic factors impacting efficacy of first-line chemoimmunotherapy in advanced NSCLC","volume":"18","author":"Alessi","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.gendis.2026.102230_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107510","article-title":"Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11\/KEAP1 comutations across PD-L1 levels","volume":"190","author":"Sun","year":"2024","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.gendis.2026.102230_bib97","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.annonc.2022.12.002","article-title":"Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma","volume":"34","author":"Scalera","year":"2023","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.gendis.2026.102230_bib98","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/j.annonc.2020.08.2105","article-title":"KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden","volume":"31","author":"Marinelli","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.gendis.2026.102230_bib99","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-25050-3","article-title":"Non-small cell lung cancer carrying PBRM1 mutation suggests an immunologically cold phenotype leading to immunotherapy failure even with high TMB","volume":"12","author":"Miao","year":"2022","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.gendis.2026.102230_bib100","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1158\/0008-5472.CAN-20-3564","article-title":"Inhibition of granulocytic myeloid-derived suppressor cells overcomes resistance to immune checkpoint inhibition in LKB1-deficient non-small cell lung cancer","volume":"81","author":"Li","year":"2021","journal-title":"Cancer Res"},{"issue":"8038","key":"10.1016\/j.gendis.2026.102230_bib101","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41586-024-07943-7","article-title":"CTLA4 blockade abrogates KEAP1\/STK11-related resistance to PD-(L)1 inhibitors","volume":"635","author":"Skoulidis","year":"2024","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.gendis.2026.102230_bib102","doi-asserted-by":"crossref","DOI":"10.1200\/PO.23.00371","article-title":"Influence of TP53 comutation on the tumor immune microenvironment and clinical outcomes with immune checkpoint inhibitors in STK11-mutant non\u2013small-cell lung cancer","author":"Naqash","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.gendis.2026.102230_bib103","article-title":"Metformin combining PD-1 inhibitor enhanced anti-tumor efficacy in STK11 mutant lung cancer through AXIN-1-dependent inhibition of STING ubiquitination","volume":"9","author":"Wang","year":"2022","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.gendis.2026.102230_bib104","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejca.2022.04.025","article-title":"The regulation of CD73 in non-small cell lung cancer","volume":"170","author":"Han","year":"2022","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.gendis.2026.102230_bib105","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1158\/1535-7163.MCT-20-0076","article-title":"Dual mechanisms of novel CD73-targeted antibody and antibody\u2013drug conjugate in inhibiting lung tumor growth and promoting antitumor immune-effector function","volume":"19","author":"Jin","year":"2020","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"10.1016\/j.gendis.2026.102230_bib106","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/1759-7714.13346","article-title":"Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC","volume":"11","author":"Ishii","year":"2020","journal-title":"Thorac Cancer"},{"issue":"23","key":"10.1016\/j.gendis.2026.102230_bib107","doi-asserted-by":"crossref","first-page":"5706","DOI":"10.3390\/cancers15235706","article-title":"Unraveling the intricacies of CD73\/Adenosine signaling: the pulmonary immune and stromal microenvironment in lung cancer","volume":"15","author":"Saig\u00ed","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.gendis.2026.102230_bib108","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.3389\/fimmu.2020.01479","article-title":"Targeting immunometabolism mediated by CD73 pathway in EGFR-mutated non-small cell lung cancer: a new hope for overcoming immune resistance","volume":"11","author":"Passarelli","year":"2020","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.gendis.2026.102230_bib109","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.celrep.2019.04.091","article-title":"Blocking antibodies targeting the CD39\/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies","volume":"27","author":"Perrot","year":"2019","journal-title":"Cell Rep"},{"issue":"12","key":"10.1016\/j.gendis.2026.102230_bib110","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.tranon.2019.08.005","article-title":"Mast cells are directly activated by cancer cell\u2013derived extracellular vesicles by a CD73- and adenosine-dependent mechanism","volume":"12","author":"Gorzalczany","year":"2019","journal-title":"Transl Oncol"},{"issue":"3","key":"10.1016\/j.gendis.2026.102230_bib111","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1172\/JCI128895","article-title":"CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment","volume":"130","author":"Neo","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.gendis.2026.102230_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119826","article-title":"Regulation of immune responses through CD39 and CD73 in cancer: novel checkpoints","volume":"282","author":"Baghbani","year":"2021","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.gendis.2026.102230_bib113","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1940675","article-title":"T cells drive negative feedback mechanisms in cancer associated fibroblasts, promoting expression of co-inhibitory ligands, CD73 and IL-27 in non-small cell lung cancer","volume":"10","author":"O\u2019Connor","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.gendis.2026.102230_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118389","article-title":"Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways","volume":"259","author":"Giatromanolaki","year":"2020","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.gendis.2026.102230_bib115","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-023-01439-z","article-title":"The Notch signaling pathway: a potential target for cancer immunotherapy","volume":"16","author":"Li","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.gendis.2026.102230_bib116","article-title":"The impact of NOTCH pathway alteration on tumor microenvironment and clinical survival of immune checkpoint inhibitors in NSCLC","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.gendis.2026.102230_bib117","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000946","article-title":"Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes","volume":"8","author":"Mazzotta","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.gendis.2026.102230_bib118","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12916-021-02031-3","article-title":"Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy","volume":"19","author":"Long","year":"2021","journal-title":"BMC Med"},{"key":"10.1016\/j.gendis.2026.102230_bib119","article-title":"NOTCH4 mutation as predictive biomarker for immunotherapy benefits in NRAS wildtype melanoma","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"issue":"14","key":"10.1016\/j.gendis.2026.102230_bib120","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1158\/1078-0432.CCR-19-3976","article-title":"Identification of deleterious NOTCH mutation as novel predictor to efficacious immunotherapy in NSCLC","volume":"26","author":"Zhang","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.gendis.2026.102230_bib121","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1158\/2326-6066.CIR-23-0037","article-title":"Notch signaling regulates immunosuppressive tumor-associated macrophage function in pancreatic cancer","volume":"12","author":"Yan","year":"2024","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.gendis.2026.102230_bib122","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1158\/1055-9965.EPI-15-0649","article-title":"A cross-cancer genetic association analysis of the DNA repair and DNA damage signaling pathways for lung, ovary, prostate, breast, and colorectal cancer","volume":"25","author":"Scarbrough","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"22","key":"10.1016\/j.gendis.2026.102230_bib123","doi-asserted-by":"crossref","first-page":"6486","DOI":"10.1158\/0008-5472.CAN-18-1814","article-title":"Comutations in DNA damage response pathways serve as potential biomarkers for immune checkpoint blockade","volume":"78","author":"Wang","year":"2018","journal-title":"Cancer Res"},{"issue":"15","key":"10.1016\/j.gendis.2026.102230_bib124","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1158\/1078-0432.CCR-19-3529","article-title":"Impact of DNA damage response and repair (DDR) gene mutations on efficacy of PD-(L)1 immune checkpoint inhibition in non\u2013small cell lung cancer","volume":"26","author":"Ricciuti","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.gendis.2026.102230_bib125","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.708558","article-title":"Comutations in DDR pathways predict atezolizumab response in non-small cell lung cancer patients","volume":"12","author":"Xiong","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.gendis.2026.102230_bib126","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s13046-022-02469-0","article-title":"The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy","volume":"41","author":"Shi","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.gendis.2026.102230_bib127","article-title":"Cancer cell-autonomous overactivation of PARP1 compromises immunosurveillance in non-small cell lung cancer","volume":"10","author":"Pan","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.gendis.2026.102230_bib128","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1016\/j.cllc.2020.07.014","volume":"22","author":"Passiglia","year":"2021","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"10.1016\/j.gendis.2026.102230_bib129","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/cncr.33885","article-title":"JASPER: phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer","volume":"128","author":"Ramalingam","year":"2022","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.gendis.2026.102230_bib130","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1158\/0008-5472.CAN-22-1740","article-title":"PARP inhibition induces synthetic lethality and adaptive immunity in LKB1-mutant lung cancer","volume":"83","author":"Long","year":"2023","journal-title":"Cancer Res"},{"issue":"16","key":"10.1016\/j.gendis.2026.102230_bib131","doi-asserted-by":"crossref","first-page":"912","DOI":"10.21037\/atm-22-3582","article-title":"A lung adenocarcinoma patient with ROS1 fusion and NBN germline mutation achieves long progression-free survival from sintilimab combined with niraparib after failure of ROS1 inhibitors: a case report","volume":"10","author":"Xu","year":"2022","journal-title":"Ann Transl Med"},{"issue":"1","key":"10.1016\/j.gendis.2026.102230_bib132","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/imr.12765","article-title":"STING pathway agonism as a cancer therapeutic","volume":"290","author":"Flood","year":"2019","journal-title":"Immunol Rev"},{"key":"10.1016\/j.gendis.2026.102230_bib133","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.795401","article-title":"The cGAS\/STING pathway: a novel target for cancer therapy","volume":"12","author":"Gan","year":"2022","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.gendis.2026.102230_bib134","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1007\/s00262-022-03220-6","article-title":"Improvement of STING-mediated cancer immunotherapy using immune checkpoint inhibitors as a game-changer","volume":"71","author":"Lee","year":"2022","journal-title":"Cancer Immunol Immunother"},{"issue":"22","key":"10.1016\/j.gendis.2026.102230_bib135","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242216274","article-title":"Tumor regression upon intratumoral and subcutaneous dosing of the STING agonist ALG-031048 in mouse efficacy models","volume":"24","author":"Jekle","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.gendis.2026.102230_bib136","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1073\/pnas.1621363114","article-title":"cGAS is essential for the antitumor effect of immune checkpoint blockade","volume":"114","author":"Wang","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.gendis.2026.102230_bib137","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002852","article-title":"STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation","volume":"9","author":"Nakamura","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.gendis.2026.102230_bib138","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1158\/1078-0432.CCR-22-2235","article-title":"Combination of the STING agonist MIW815 (ADU-S100) and PD-1 inhibitor spartalizumab in advanced\/metastatic solid tumors or lymphomas: an open-label, multicenter, phase ib study","volume":"29","author":"Meric-Bernstam","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.gendis.2026.102230_bib139","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1158\/1078-0432.CCR-23-0118","article-title":"Phase I study of SYNB1891, an Engineered E. coli Nissle strain expressing STING agonist, with and without atezolizumab in advanced malignancies","volume":"29","author":"Luke","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.gendis.2026.102230_bib140","article-title":"STING agonist inflames the cervical cancer immune microenvironment and overcomes anti-PD-1 therapy resistance","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.gendis.2026.102230_bib141","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.3390\/jcm9103323","article-title":"Challenges and opportunities in the clinical development of STING agonists for cancer immunotherapy","volume":"9","author":"Motedayen","year":"2020","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.gendis.2026.102230_bib142","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3390\/biomedicines11010190","article-title":"Wnt\/\u03b2-catenin signaling and resistance to immune checkpoint inhibitors: from non-small-cell lung cancer to other cancers","volume":"11","author":"Muto","year":"2023","journal-title":"Biomedicines"},{"issue":"10","key":"10.1016\/j.gendis.2026.102230_bib143","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-18-1942","article-title":"WNT\/\u03b2-catenin pathway activation correlates with immune exclusion across human cancers","volume":"25","author":"Luke","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"65","key":"10.1016\/j.gendis.2026.102230_bib144","doi-asserted-by":"crossref","first-page":"eabc6424","DOI":"10.1126\/sciimmunol.abc6424","article-title":"Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape","volume":"6","author":"Takeuchi","year":"2021","journal-title":"Sci Immunol"},{"issue":"1","key":"10.1016\/j.gendis.2026.102230_bib145","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10238-023-01274-z","article-title":"WNT\/\u03b2-catenin regulatory roles on PD-(L)1 and immunotherapy responses","volume":"24","author":"Mortezaee","year":"2024","journal-title":"Clin Exp Med"},{"issue":"5","key":"10.1016\/j.gendis.2026.102230_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109071","article-title":"Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy","volume":"35","author":"DeVito","year":"2021","journal-title":"Cell Rep"},{"issue":"7","key":"10.1016\/j.gendis.2026.102230_bib147","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1158\/1535-7163.MCT-20-0825","article-title":"Blocking Wnt\/\u03b2-catenin signal amplifies anti-PD-1 therapeutic efficacy by inhibiting tumor growth, migration, and promoting immune infiltration in glioblastomas","volume":"20","author":"Zhang","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.gendis.2026.102230_bib148","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2174\/1874467214666210617163821","article-title":"Disruption of Wnt\/\u03b2-catenin pathway elevates the sensitivity of gastric cancer cells to PD-1 antibody","volume":"15","author":"Li","year":"2022","journal-title":"Curr Mol Pharmacol"},{"key":"10.1016\/j.gendis.2026.102230_bib149","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20220503","article-title":"WNT signaling in the tumor microenvironment promotes immunosuppression in murine pancreatic cancer","volume":"220","author":"Du","year":"2023","journal-title":"J Exp Med"},{"key":"10.1016\/j.gendis.2026.102230_bib150","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.667875","article-title":"TNF-alpha pathway alternation predicts survival of immune checkpoint inhibitors in non-small cell lung cancer","volume":"12","author":"Lin","year":"2021","journal-title":"Front Immunol"},{"issue":"16","key":"10.1016\/j.gendis.2026.102230_bib151","doi-asserted-by":"crossref","first-page":"8691","DOI":"10.3390\/ijms22168691","article-title":"TNF\u03b1 and immune checkpoint inhibition: friend or foe for lung cancer?","volume":"22","author":"Benoot","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.gendis.2026.102230_bib152","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003982","article-title":"Combination cancer immunotherapy targeting TNFR2 and PD-1\/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors","volume":"10","author":"Zhang","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.gendis.2026.102230_bib153","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/cam4.4852","article-title":"First-line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 insertions: real-world evidence from China","volume":"12","author":"Yang","year":"2023","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.gendis.2026.102230_bib154","article-title":"Comprehensive analysis identifies PI3K\/Akt pathway alternations as an immune-related prognostic biomarker in colon adenocarcinoma patients receiving immune checkpoint inhibitor treatment","volume":"2022","author":"Lin","year":"2022","journal-title":"J Immunol Res"},{"key":"10.1016\/j.gendis.2026.102230_bib155","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241289671","article-title":"CD34 as a potential prognostic indicator for camrelizumab response in advanced non-small-cell lung cancer: insights from digital spatial profiling","volume":"16","author":"Huang","year":"2024","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.gendis.2026.102230_bib156","doi-asserted-by":"crossref","DOI":"10.1080\/15384047.2024.2301801","article-title":"The critical role of tumor microbiome in cancer immunotherapy","volume":"25","author":"Yang","year":"2024","journal-title":"Cancer Biol Ther"},{"issue":"6371","key":"10.1016\/j.gendis.2026.102230_bib157","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti\u2013PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.gendis.2026.102230_bib158","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.3390\/cancers16101806","article-title":"Gut microbiota are a novel source of biomarkers for immunotherapy in non-small-cell lung cancer (NSCLC)","volume":"16","author":"Del Giudice","year":"2024","journal-title":"Cancers"},{"issue":"28","key":"10.1016\/j.gendis.2026.102230_bib159","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.23.01488","article-title":"Intratumoral Escherichia is associated with improved survival to single-agent immune checkpoint inhibition in patients with advanced non\u2013small-cell lung cancer","volume":"42","author":"Elkrief","year":"2024","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.gendis.2026.102230_bib160","doi-asserted-by":"crossref","first-page":"9019","DOI":"10.3390\/cimb45110566","article-title":"Advances in CAR T cell therapy for non-small cell lung cancer","volume":"45","author":"Ma","year":"2023","journal-title":"Curr Issues Mol Biol"},{"key":"10.1016\/j.gendis.2026.102230_bib161","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-68779-9","article-title":"CD98 heavy chain protein is overexpressed in non-small cell lung cancer and is a potential target for CAR T-cell therapy","volume":"14","author":"Yaga","year":"2024","journal-title":"Sci Rep"},{"issue":"21","key":"10.1016\/j.gendis.2026.102230_bib162","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.3390\/cancers16213603","article-title":"Novel immunotherapeutics for the treatment of non-small cell lung cancer (NSCLC) resistant to PD-1\/PD-L1 inhibitors","volume":"16","author":"Malhotra","year":"2024","journal-title":"Cancers"}],"container-title":["Genes & Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304226002023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304226002023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:12:40Z","timestamp":1790111560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352304226002023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":162,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2027,1]]}},"alternative-id":["S2352304226002023"],"URL":"https:\/\/doi.org\/10.1016\/j.gendis.2026.102230","relation":{},"ISSN":["2352-3042"],"issn-type":[{"value":"2352-3042","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of oncogenic drivers and signaling pathways on immune checkpoint inhibitor efficacy in NSCLC","name":"articletitle","label":"Article Title"},{"value":"Genes & Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gendis.2026.102230","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102230"}}